Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
Hematological Oncology
|
June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
Claudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study
Nicola Sgherza, Olga Battisti, Paola Curci, et al.
Pharmaceuticals (Basel, Switzerland)
|
June 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595
Nicola Sgherza, Olga Battisti, Paola Curci, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Critical Reviews in Oncology/Hematology
|
November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
European Journal of Haematology
|
September 25, 2023
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance
Gaetano Giuffrida, Uros Markovic, Annalisa Condorelli, et al.
Annals of Hematology
|
October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
Annals of Hematology
|
May 28, 2024
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
Giuseppe Mele, Daniele Derudas, Concetta Conticello, et al.
Journal of Clinical Medicine
|
June 29, 2019
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
Concetta Conticello, Alessandra Romano, Vittorio Del Fabro, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
Hematological Oncology
|
June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
Claudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
Pharmaceuticals (Basel, Switzerland)
|
April 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study
Nicola Sgherza, Olga Battisti, Paola Curci, et al.
Pharmaceuticals (Basel, Switzerland)
|
June 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595
Nicola Sgherza, Olga Battisti, Paola Curci, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Critical Reviews in Oncology/Hematology
|
November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
European Journal of Haematology
|
September 25, 2023
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance
Gaetano Giuffrida, Uros Markovic, Annalisa Condorelli, et al.
Annals of Hematology
|
October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
Annals of Hematology
|
May 28, 2024
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
Giuseppe Mele, Daniele Derudas, Concetta Conticello, et al.
Journal of Clinical Medicine
|
June 29, 2019
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
Concetta Conticello, Alessandra Romano, Vittorio Del Fabro, et al.
Page
of 10